AU2016345462A1 - D-proline derivatives as SAP depleting agent - Google Patents
D-proline derivatives as SAP depleting agent Download PDFInfo
- Publication number
- AU2016345462A1 AU2016345462A1 AU2016345462A AU2016345462A AU2016345462A1 AU 2016345462 A1 AU2016345462 A1 AU 2016345462A1 AU 2016345462 A AU2016345462 A AU 2016345462A AU 2016345462 A AU2016345462 A AU 2016345462A AU 2016345462 A1 AU2016345462 A1 AU 2016345462A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- sap
- formula
- disease
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1518950.9A GB201518950D0 (en) | 2015-10-27 | 2015-10-27 | Compound |
| GB1518950.9 | 2015-10-27 | ||
| PCT/EP2016/075632 WO2017072099A1 (en) | 2015-10-27 | 2016-10-25 | D-proline derivatives as sap depleting agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016345462A1 true AU2016345462A1 (en) | 2018-04-26 |
Family
ID=55130261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016345462A Abandoned AU2016345462A1 (en) | 2015-10-27 | 2016-10-25 | D-proline derivatives as SAP depleting agent |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10328052B2 (enExample) |
| EP (1) | EP3368532B1 (enExample) |
| JP (2) | JP6789288B2 (enExample) |
| KR (1) | KR20180067559A (enExample) |
| CN (1) | CN108368095B (enExample) |
| AU (1) | AU2016345462A1 (enExample) |
| BR (1) | BR112018008582A2 (enExample) |
| CA (1) | CA3002710A1 (enExample) |
| ES (1) | ES2781550T3 (enExample) |
| GB (1) | GB201518950D0 (enExample) |
| RU (1) | RU2018119120A (enExample) |
| WO (1) | WO2017072099A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202111866D0 (en) | 2021-08-18 | 2021-09-29 | Ucl Business Plc | Prodrugs for use in the treatment of tissue damage |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859031A (en) * | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| PT915088E (pt) * | 1997-10-31 | 2003-01-31 | Hoffmann La Roche | Derivados de d-prolina |
| US6903129B2 (en) * | 2001-12-14 | 2005-06-07 | Hoffman-La Roche Inc. | D-proline prodrugs |
| US7265140B2 (en) | 2003-09-23 | 2007-09-04 | Pfizer Inc | Acyloxymethylcarbamate prodrugs of oxazolidinones |
| US8236792B2 (en) * | 2008-05-23 | 2012-08-07 | Janssen Pharmaceutica Nv | Substituted pyrrolidine amides as modulators of the histamine H3 receptor |
| US9737505B2 (en) | 2014-04-29 | 2017-08-22 | Glaxosmithkline Intellectual Property Development Limited | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline |
| GB201407506D0 (en) * | 2014-04-29 | 2014-06-11 | Glaxosmithkline Ip Dev Ltd | Novel compound |
-
2015
- 2015-10-27 GB GBGB1518950.9A patent/GB201518950D0/en not_active Ceased
-
2016
- 2016-10-25 CA CA3002710A patent/CA3002710A1/en not_active Abandoned
- 2016-10-25 KR KR1020187011871A patent/KR20180067559A/ko not_active Withdrawn
- 2016-10-25 EP EP16823162.9A patent/EP3368532B1/en active Active
- 2016-10-25 BR BR112018008582A patent/BR112018008582A2/pt not_active Application Discontinuation
- 2016-10-25 US US15/771,442 patent/US10328052B2/en active Active
- 2016-10-25 JP JP2018521655A patent/JP6789288B2/ja not_active Expired - Fee Related
- 2016-10-25 CN CN201680073108.0A patent/CN108368095B/zh not_active Expired - Fee Related
- 2016-10-25 RU RU2018119120A patent/RU2018119120A/ru not_active Application Discontinuation
- 2016-10-25 AU AU2016345462A patent/AU2016345462A1/en not_active Abandoned
- 2016-10-25 ES ES16823162T patent/ES2781550T3/es active Active
- 2016-10-25 WO PCT/EP2016/075632 patent/WO2017072099A1/en not_active Ceased
-
2020
- 2020-10-30 JP JP2020182835A patent/JP7053762B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3368532A1 (en) | 2018-09-05 |
| JP6789288B2 (ja) | 2020-11-25 |
| JP2018531967A (ja) | 2018-11-01 |
| JP2021035963A (ja) | 2021-03-04 |
| KR20180067559A (ko) | 2018-06-20 |
| RU2018119120A (ru) | 2019-11-28 |
| EP3368532B1 (en) | 2020-01-15 |
| BR112018008582A2 (pt) | 2018-10-30 |
| ES2781550T3 (es) | 2020-09-03 |
| GB201518950D0 (en) | 2015-12-09 |
| CN108368095A (zh) | 2018-08-03 |
| CN108368095B (zh) | 2021-06-08 |
| US10328052B2 (en) | 2019-06-25 |
| CA3002710A1 (en) | 2017-05-04 |
| US20190060274A1 (en) | 2019-02-28 |
| JP7053762B2 (ja) | 2022-04-12 |
| WO2017072099A1 (en) | 2017-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018177788A (ja) | Ntcp阻害剤によるアテローム性動脈硬化、原発性胆汁性肝硬変およびnrlp3インフラマソーム関連疾患の治療 | |
| US9737505B2 (en) | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline | |
| IL292522A (en) | Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi | |
| US10597385B2 (en) | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline | |
| WO2022251539A2 (en) | Egfr degraders to treat cancer metastasis to the brain or cns | |
| CN117940407A (zh) | 降低免疫不耐受和治疗自身免疫病症的组合物和方法 | |
| EP3368532B1 (en) | D-proline derivative as sap depleting agent | |
| CN114025766A (zh) | 用于抑制gapdh的噁噻嗪化合物 | |
| WO2023165459A1 (en) | Compounds as sars-cov-2 inhibitors | |
| US20180230185A1 (en) | Peptidomimetics for Treating HER2-Overexpressd Cancer | |
| CA2568213C (en) | Composition and method for the treatment of tauopathies | |
| EP4178945B1 (en) | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | |
| WO2025015254A2 (en) | Therapeutic agent composition and method of use of combination therapy for treatment of mild cognitive impairment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |